摘要
目的:分析卡瑞利珠单抗致反应性毛细血管增生症(RCCEP)的一般规律及特点,为临床安全用药提供参考。方法:检索PubMed、Web of Science、Embase、万方、中国知网、维普数据库,检索时间为自建库至2022年7月,收集卡瑞利珠单抗相关RCCEP的个案报道,对患者性别、年龄、用药情况、RCCEP发生时间、临床表现等进行统计分析。结果:共收集文献16篇,纳入病例19例,患者年龄35~72岁,41~65岁患者最多(73.68%);RCCEP发生时间多为开始给药的15~21 d(47.37%),累及皮肤(82.21%)、牙龈(10.53%)以及乳腺(5.26%)。结论:临床应了解卡瑞利珠单抗所致RCCEP的规律和特点,加强对该药的合理使用与临床监测,保障患者用药安全。
Objective:To analyze the general rules and characteristics of reactive cutaneous capillary endothelial proliferation(RCCEP)caused by camrelizumab,in order to provide references for clinical safety drug use.Methods:Case reports of RCCEP induced by camrelizumab were searched in PubMed,Web of Science,Embase,Wanfang,CNKI,VIP databases up to July 2022 and statistically analyzed in terms of gender,age,medication,occurrence time and clinical manifestations of RCCEP.Results:A total of 16 literature,19 cases were enrolled in this study.The age of the patients ranged from 35 to 72 years old,among which most patients were aged from 41 to 65 years old(73.68%).RCCEP mostly occurred within 15–21 days after administration(47.37%),which involved skin(82.21%),gingiva(10.53%)and breast(5.26%).Conclusion:We should be aware of the rules and characteristics of RCCEP caused by camrelizumab,strengthen rational use and monitoring of camrelizumab in order to ensure the drug safety of patients.
作者
乔逸
陈苏宁
郭桂萍
王聪聪
葛洁
曹珊珊
张维
关月
王婧雯
QIAO Yi;CHEN Su-ning;GUO Gui-ping;WANG Cong-cong;GE Jie;CAO Shan-shan;ZHANG Wei;GUAN Yue;WANG Jing-wen(Department of Pharmacy,Xying Hospital,Air Force Military Medical University,Xi'an 710032,China)
出处
《中国药物应用与监测》
CAS
2022年第6期390-393,共4页
Chinese Journal of Drug Application and Monitoring
基金
国家自然科学基金项目(72074218)。
关键词
卡瑞利珠单抗
反应性毛细血管增生症
药品不良反应
文献分析
Camrelizumab
Reactive cutaneous capillary endothelial proliferation
Adverse drug reaction
Literature analysis
